Avecho Biotechnology Ltd (ASX: AVE) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Avecho Biotechnology Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $9.51 million
P/E Ratio 17.99
Dividend Yield 0.00%
Shares Outstanding 3.17 billion
Earnings per share -0.002
Dividend per share N/A
Year To Date Return -28.57%
Earnings Yield 5.56%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Avecho Biotechnology Ltd (ASX: AVE)
    Latest News

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in

    After some strong support in early 2021, biotechnology stocks took a beating over the past 6 months.

    Read more »

    jump in asx share price represented by man leaping up from one wooden pillar to the next
    Share Market News

    Avecho (ASX:AVE) share price rockets 83% on milestone announcement

    The Avecho Biotechnology Ltd (ASX: AVE) share price is beating the All Ordinaries Index (ASX: XAO) by a mile today.…

    Read more »

    AVE ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Avecho Biotechnology Ltd

    Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphoneand TPM/Oxycodone.

    AVE Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Jul 2024 $0.00 $0.00 0.00% 154,216 $0.00 $0.00 $0.00
    18 Jul 2024 $0.00 $0.00 0.00% 152,948 $0.00 $0.00 $0.00
    17 Jul 2024 $0.00 $0.00 0.00% 10,943 $0.00 $0.00 $0.00
    16 Jul 2024 $0.00 $0.00 0.00% 1,175,056 $0.00 $0.00 $0.00
    15 Jul 2024 $0.00 $0.00 0.00% 1,535,981 $0.00 $0.00 $0.00
    12 Jul 2024 $0.00 $0.00 0.00% 4,335,311 $0.00 $0.00 $0.00
    11 Jul 2024 $0.00 $0.00 0.00% 594,397 $0.00 $0.00 $0.00
    10 Jul 2024 $0.00 $0.00 0.00% 878,370 $0.00 $0.00 $0.00
    09 Jul 2024 $0.00 $0.00 0.00% 455,774 $0.00 $0.00 $0.00
    08 Jul 2024 $0.00 $0.00 0.00% 508,178 $0.00 $0.00 $0.00
    04 Jul 2024 $0.00 $0.00 0.00% 3,064,000 $0.00 $0.00 $0.00
    03 Jul 2024 $0.00 $0.00 0.00% 1,148,149 $0.00 $0.00 $0.00
    02 Jul 2024 $0.00 $0.00 0.00% 7,000 $0.00 $0.00 $0.00
    01 Jul 2024 $0.00 $0.00 0.00% 751,902 $0.00 $0.00 $0.00
    28 Jun 2024 $0.00 $0.00 0.00% 1,445,123 $0.00 $0.00 $0.00
    27 Jun 2024 $0.00 $0.00 0.00% 5,204,381 $0.00 $0.00 $0.00
    26 Jun 2024 $0.00 $0.00 0.00% 494,810 $0.00 $0.00 $0.00
    25 Jun 2024 $0.00 $0.00 0.00% 350,464 $0.00 $0.00 $0.00
    24 Jun 2024 $0.00 $0.00 0.00% 76,533 $0.00 $0.00 $0.00
    21 Jun 2024 $0.00 $0.00 0.00% 2,204,941 $0.00 $0.00 $0.00
    20 Jun 2024 $0.00 $0.00 0.00% 2,788,030 $0.00 $0.00 $0.00
    19 Jun 2024 $0.00 $0.00 0.00% 82,616 $0.00 $0.00 $0.00

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    22 Nov 2023 Gregory (Greg) Collier Issued 8,749,999 $34,999
    Issue of securities.
    22 Nov 2023 Gregory (Greg) Collier Issued 5,833,333 $34,999
    Issue of securities.
    22 Nov 2023 Matthew McNamara Issued 2,499,999 $9,999
    Issue of securities.
    22 Nov 2023 Matthew McNamara Issued 1,666,666 $9,999
    Issue of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Gregory (Greg) Collier Non-Executive ChairmanNon-Executive Director Apr 2019
    Dr Collier has more than 25' years experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. Dr Collier has led the planning and execution of multiple commercial transactions including in and out licensing deals and major M&A activities, and he has taken a drug from discovery through to regulatory approval. Notably, Dr Collier steered ChemGenex Pharmaceuticals Limited from a research based Company with a market capitalisation of $10 million to a Company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon Inc. (now subsidiary of Teva Pharmaceuticals Industries Limited) for $230 million. Prior to his commercial pharmaceutical career, Dr Collier had an academic career resulting in over 150 peer reviewed publications, and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto. In 2010, Dr Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.
    Dr Ross Murdoch Non-Executive Director Apr 2015
    Dr Murdoch has almost 30 years' experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses. Highlights of his career include Senior Vice President at Shire Pharmaceuticals (one of the specialty pharmaceutical companies), based in the USA and Switzerland, where he founded and grew both the Emerging Products Business and Haematology Business and President and COO of Prana Biotechnology Limited based in Australia.
    Mr Matthew Patrick McNamara Non-Executive Director Jan 2020
    Mr McNamara has over 30 years' executive and funds management experience in the healthcare and medical sciences sector. In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology / investment companies. Mr McNamara is currently Director and Chief Investment Officer of Horizon 3 Healthcare, a healthcare fund manager that has invested in Avecho Biotechnology Limited through trustee Melbourne Securities Corporation Limited. He is presently a director of Microbio Pty Ltd, ESN Cleer Pty Ltd and Cardiac Dimensions Pty Ltd. He has held previous directorship in Saluda Medical Pty Ltd. Mr McNamara has also served as CIO of BioScience Manager Pty Ltd, and was CEO of SciCapital Pty Ltd, a Life Sciences Venture Capital fund.
    Ms Katherine(Kathy) Ellen Danielle Connell Non-Executive Director Apr 2024
    Ms Connell is an internationally recognised healthcare and lifesciences leader with investment and licensing expertise. For the past 20 years, Kathy has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors in business development, licensing, acquisitions and venture investment, including 12 years at Johnson & Johnson as Senior Director, New Ventures ANZ. Kathy co-founded Medicines Australias Pharmaceutical Australia Inclusion Group (PAIG) - a working group designed to foster diverse and inclusive corporate cultures across the pharmaceutical industries. Today Kathy leads Korn Ferrys Healthcare and LifeSciences practice in Australia as Senior Client Partner and she is also a Non-Executive Director of BioNSW.
    Ms Melanie Jaye Leydin Chief Financial OfficerCompany Secretary Dec 2018
    -
    Dr Paul Gavin Chief Executive Officer May 2020
    -
    Paul Gavin Chief Executive Officer
    -
    Melanie Jaye Leydin Chief Financial OfficerCompany Secretary
    -
    Roksan Libinaki Chief Operating officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr Mark Gregory Kerr and Mrs Linda Marie Kerr <Lindmark Inv Staff S/F A/C> 349,133,188 11.02%
    Ms Chunyan Niu 250,000,000 7.89%
    Rosscope Pty Ltd <Ross Copeland Family A/C> 85,513,129 2.70%
    Hsbc Custody Nominees (Australia) Limited 84,056,019 2.65%
    Melbourne Securities Corporation Limited <Horizon 3 Biotech Fund A/C> 59,345,624 1.87%
    Jawess Pty Ltd <Kent Family Super Fund A/C> 50,000,000 1.58%
    Hirsch Financial Pty Ltd 49,878,323 1.57%
    Mr Brandon Armon Batagol 44,532,406 1.41%
    Melbourne Securities Corporation Limited <Horizon 3 Healthcare A/C> 41,666,666 1.31%
    Bnp Paribas Noms Pty Ltd 39,367,251 1.24%
    180 Markets Pty Ltd 38,333,333 1.21%
    1215 Capital Pty Ltd 33,801,008 1.07%
    Hunt Prosperity Pty Ltd <Investius PB Micro Cap A/C> 33,333,333 1.05%
    Mcneil Nominees Pty Limited 33,333,333 1.05%
    Servbond Pty Limited <Servbond Pty Ltd S/F A/C> 31,000,000 0.98%
    Mr David Segal 23,000,000 0.73%
    Mr Raymond Laurence Carroll 22,500,000 0.71%
    Mr Tony Domenic Amato 22,000,000 0.69%
    Citicorp Nominees Pty Limited 20,970,215 0.66%
    FF Okram Pty Ltd <FF Okram A/C> 20,494,147 0.65%

    Profile

    since

    Note